Grantham, Mayo, Van Otterloo & Co (GMO)
JAZZ icon

Grantham, Mayo, Van Otterloo & Co (GMO)’s Jazz Pharmaceuticals JAZZ Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,267
Closed -$241K – 632
2025
Q2 		$241K Sell
2,267
-5,854
-72% -$636K ﹤0.01% 580
2025
Q1 		$1.01M Sell
8,121
-16,994
-68% -$2.22M ﹤0.01% 457
2024
Q4 		$3.09M Buy
25,115
+22,108
+735% +$2.61M 0.01% 341
2024
Q3 		$335K Sell
3,007
-5,324
-64% -$583K ﹤0.01% 518
2024
Q2 		$889K Sell
8,331
-185,869
-96% -$20.4M ﹤0.01% 405
2024
Q1 		$23.4M Sell
194,200
-13,558
-7% -$1.66M 0.09% 169
2023
Q4 		$25.6M Buy
207,758
+25,076
+14% +$3.13M 0.11% 139
2023
Q3 		$23.6M Sell
182,682
-1,295
-0.7% -$173K 0.11% 159
2023
Q2 		$22.8M Sell
183,977
-44,723
-20% -$6.02M 0.11% 169
2023
Q1 		$33.5M Sell
228,700
-2,900
-1% -$429K 0.17% 124
2022
Q4 		$36.9M Buy
231,600
+29,600
+15% +$4.34M 0.2% 106
2022
Q3 		$26.9M Buy
202,000
+5,100
+3% +$775K 0.16% 132
2022
Q2 		$30.7M Sell
196,900
-4,800
-2% -$739K 0.17% 119
2022
Q1 		$31.4M Buy
201,700
+22,100
+12% +$3.21M 0.15% 121
2021
Q4 		$22.9M Buy
179,600
+3,100
+2% +$407K 0.11% 153
2021
Q3 		$23M Buy
176,500
+28,600
+19% +$4.32M 0.11% 150
2021
Q2 		$26.3M Buy
147,900
+30,100
+26% +$5.21M 0.13% 135
2021
Q1 		$19.4M Buy
117,800
+27,600
+31% +$4.54M 0.11% 154
2020
Q4 		$14.9M Buy
+90,200
New +$13.4M 0.09% 148

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s JAZZ Position: Q3 2025 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2025, closing a stake of 2,267 shares — an estimated $241K sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in JAZZ in Q4 2020 and held it in 19 quarters. The position peaked at $36.9M in Q4 2022. 503 funds tracked by Wall St. Rank hold JAZZ as of Q3 2025.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Jazz Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 2,267 Jazz Pharmaceuticals shares in Q3 2025, an estimated $241K.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Jazz Pharmaceuticals in Q4 2020 and held it in 19 quarters.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Jazz Pharmaceuticals position peaked at $36.9M in Q4 2022.
  • 503 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2025.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q3 2025, filed 13 Nov 2025.